Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 61 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NH3n[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\iPWlEPTB;MD6wOlEh|ryP NHPMVlJUSU6JRWK=
ALL-PO NHWycnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETvV5dKSzVyPUCuNFY{PTVizszN NI\6Z4pUSU6JRWK=
697 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j0SGlEPTB;MD6wPVk4PiEQvF2= MXjTRW5ITVJ?
NCI-H748 NWTRbFk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi1NJAxUUN3ME2wMlExOzN2IN88US=> M1LvUnNCVkeHUh?=
NKM-1 NHrNb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LpZWlEPTB;MD6xNFkyOiEQvF2= MkT6V2FPT0WU
ES1 NVP6R5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfT[m9QUUN3ME2wMlEyOjV3IN88US=> MVHTRW5ITVJ?
NCI-H1963 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX34ephEUUN3ME2wMlEyPTd7IN88US=> NIS2cYdUSU6JRWK=
NCI-H1417 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMUK5O|Qh|ryP NYnVSmN3W0GQR1XS
NEC8 NIHJU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHD[YJKSzVyPUCuNVM2OjdizszN NXLO[nA4W0GQR1XS
CRO-AP2 M1qwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\MVpJPUUN3ME2wMlE3QDh7IN88US=> MVvTRW5ITVJ?
A3-KAW M4nWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LvVWlEPTB;MD6xO|YzPyEQvF2= NWn5WVQzW0GQR1XS
SF539 M1\Pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3HZ3ppUUN3ME2wMlE6PTl|IN88US=> MlKzV2FPT0WU
NOS-1 NXTEfFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\VXnJFUUN3ME2wMlE6PjF7IN88US=> NUXRNGJmW0GQR1XS
NTERA-S-cl-D1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXflTFlIUUN3ME2wMlIxOTF|IN88US=> NEjzPW9USU6JRWK=
COR-L88 M1XMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMkK5OVkh|ryP NWP2WZVCW0GQR1XS
EM-2 NFWzeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuxXHgxUUN3ME2wMlI1ODd7IN88US=> NIXZTXNUSU6JRWK=
KARPAS-45 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDHfGZEUUN3ME2wMlI4QDN|IN88US=> MoXYV2FPT0WU
DSH1 M{OyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\0TWM2OD1yLkK4O|A5KM7:TR?= M2\vSnNCVkeHUh?=
HT-144 M3SzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\hUmlEPTB;MD6zNFI2PiEQvF2= Ml7XV2FPT0WU
ATN-1 NIGxbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrtUHp3UUN3ME2wMlMxPTd4IN88US=> Mn3MV2FPT0WU
HEL MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7tNJlKSzVyPUCuN|E{PDhizszN Mo\mV2FPT0WU
NB12 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3WzeWlEPTB;MD6zNVc2PiEQvF2= MmjUV2FPT0WU
LU-139 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvGTWM2OD1yLkOzOVEh|ryP M37JUnNCVkeHUh?=
J-RT3-T3-5 NGPKXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwM{O3NVYh|ryP MX;TRW5ITVJ?
MOLT-13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moq0TWM2OD1yLkOzPFEh|ryP NGPGVphUSU6JRWK=
SR NVjLR5FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr4TWM2OD1yLkO0NlYyKM7:TR?= NYSxPHg{W0GQR1XS
CMK NFfk[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwM{W3Nlch|ryP NUjncW1rW0GQR1XS
ES8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fmfGlEPTB;MD6zOlAzOiEQvF2= M3SwU3NCVkeHUh?=
LB647-SCLC NWS3WmRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17WR2lEPTB;MD6zOlc{KM7:TR?= NVfORoZtW0GQR1XS
TE-8 NUHrfHR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i1O2lEPTB;MD6zOlk{PSEQvF2= Mn;DV2FPT0WU
BV-173 M1XLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ZTWM2OD1yLkO3NVIyKM7:TR?= M37kTHNCVkeHUh?=
DEL MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P4W2lEPTB;MD6zO|Q5PyEQvF2= Mki4V2FPT0WU
ARH-77 NILNdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nK[WlEPTB;MD6zPFE6OyEQvF2= MoHQV2FPT0WU
NCCIT NGKyU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGxdYZzUUN3ME2wMlM5PjR7IN88US=> MVHTRW5ITVJ?
RPMI-8402 NVTRO2p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\qUXNKSzVyPUCuN|g4ODFizszN NFn5OGhUSU6JRWK=
MONO-MAC-6 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzDTWM2OD1yLkO4O|c3KM7:TR?= M2L1T3NCVkeHUh?=
SK-MM-2 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrxfI5KSzVyPUCuN|k5PjhizszN MkLnV2FPT0WU
CHP-126 M1XvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDuSYtKSzVyPUCuOFAzOzFizszN MVHTRW5ITVJ?
A101D MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq3O2FKSzVyPUCuOFA{KM7:TR?= NUHSUZVVW0GQR1XS
SCH M2\ie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7zT4hsUUN3ME2wMlQxOzR{IN88US=> NXjNNYxSW0GQR1XS
NMC-G1 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTmTWM2OD1yLkSwN|Y4KM7:TR?= M2PaS3NCVkeHUh?=
NCI-H209 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnENnpKSzVyPUCuOFA3OTNizszN NIXvR4hUSU6JRWK=
MOLT-16 MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ruTmlEPTB;MD60NVAyPyEQvF2= NYTtVoJTW0GQR1XS
RPMI-6666 M1LlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwNEGxNkDPxE1? MVzTRW5ITVJ?
OPM-2 NGmwO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjSTWM2OD1yLkSxOVE{KM7:TR?= M3Hue3NCVkeHUh?=
MRK-nu-1 NFLMWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETWTHBKSzVyPUCuOFMyPTNizszN MlXKV2FPT0WU
BC-1 NGLNbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkThTWM2OD1yLkSzOFA{KM7:TR?= NGLncZhUSU6JRWK=
MHH-NB-11 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwNEO0OVMh|ryP MYHTRW5ITVJ?
Ramos-2G6-4C10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjCTWM2OD1yLkSzPFk4KM7:TR?= NVfTfnF[W0GQR1XS
LS-513 NYnBO2pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XHeWlEPTB;MD60OFUxOSEQvF2= NGP3UoxUSU6JRWK=
K5 M4W2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrudGlVUUN3ME2wMlQ4ODJ3IN88US=> M2PuNXNCVkeHUh?=
HOP-62 NHvI[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK2d2pKSzVyPUCuOFg{PThizszN M4[3ZnNCVkeHUh?=
NCI-H187 NInpcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDkTWM2OD1yLkS5NlI4KM7:TR?= M2i1Z3NCVkeHUh?=
BE-13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGw[ZU2UUN3ME2wMlQ6PjZzIN88US=> NGXINW1USU6JRWK=
HC-1 NX3ybFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;0O5RTUUN3ME2wMlUxPDd|IN88US=> Moj3V2FPT0WU
ACN MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES0XGRKSzVyPUCuOVExOjhizszN M1P1Z3NCVkeHUh?=
HCC1599 NXzMU3ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[zbnM4UUN3ME2wMlUyPTdizszN NFXJWVhUSU6JRWK=
MV-4-11 NIf1[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDOTWM2OD1yLkWzNFQyKM7:TR?= MkTlV2FPT0WU
LC-2-ad M1Xkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDlbot5UUN3ME2wMlU{PjZ|IN88US=> M4jheXNCVkeHUh?=
HL-60 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwNUSyOlEh|ryP NUfUTWJ3W0GQR1XS
NB17 NHjSUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv3TWM2OD1yLkW0N|gh|ryP NVfW[lVyW0GQR1XS
TE-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nFfGlEPTB;MD61OVMxPiEQvF2= M2jZTXNCVkeHUh?=
NCI-H524 M17YUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrIWmZKSzVyPUCuOVU1ODFizszN MoTDV2FPT0WU
MZ7-mel NV\3UpY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;WVGlEPTB;MD61OlExPSEQvF2= NV:xcWFsW0GQR1XS
L-363 NHfTXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH1TWM2OD1yLkW2OlU4KM7:TR?= NV:ybo82W0GQR1XS
BL-41 NYm3epBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PnZ2lEPTB;MD61Olg5QSEQvF2= MUfTRW5ITVJ?
LU-134-A MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTq[XZKSzVyPUCuOVcxPzNizszN M4m4fHNCVkeHUh?=
SIG-M5 NVvrXHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvidnpKSzVyPUCuOVc5PDhizszN MnXzV2FPT0WU
ONS-76 NUfM[o9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwNUiyOFIh|ryP Mln3V2FPT0WU
KARPAS-299 NH20eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HWZmlEPTB;MD61PFUxPCEQvF2= Ml7tV2FPT0WU
DU-4475 MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LWZmlEPTB;MD61PFcxOyEQvF2= M2K1WHNCVkeHUh?=
NB69 NGHZeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjDRnlnUUN3ME2wMlU6QDJ3IN88US=> MX7TRW5ITVJ?
MHH-PREB-1 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNkC3NVkh|ryP NFjVWIxUSU6JRWK=
LU-165 NFPWOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLxTWM2OD1yLk[xPFEzKM7:TR?= NIDaWo5USU6JRWK=
LOUCY M1nZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M125U2lEPTB;MD62N|M3PCEQvF2= NUfOe5VCW0GQR1XS
NCI-H526 M2XsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDNbnVKSzVyPUCuOlM2PDFizszN MX7TRW5ITVJ?
KE-37 M4XpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKxS|FKSzVyPUCuOlQzPzZizszN NVviR3k1W0GQR1XS
NALM-6 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\mTWM2OD1yLk[0PFYh|ryP MofoV2FPT0WU
CW-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTkeXA1UUN3ME2wMlY2Pzl2IN88US=> MVTTRW5ITVJ?
SU-DHL-1 M3PuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnCdpVsUUN3ME2wMlY2QTR5IN88US=> MmXPV2FPT0WU
NB13 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzSZ|RXUUN3ME2wMlY3QDF5IN88US=> M2PEOHNCVkeHUh?=
QIMR-WIL M{T3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNkizOFMh|ryP NH21OY1USU6JRWK=
ECC12 NGX2[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrLTWM2OD1yLkewNFg3KM7:TR?= NFH6V4xUSU6JRWK=
KALS-1 NF23NmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljxTWM2OD1yLkewOFkzKM7:TR?= NFfvNlRUSU6JRWK=
COR-L279 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H2WGlEPTB;MD63NFk6PiEQvF2= M1HKb3NCVkeHUh?=
NB14 NIXBXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGyflNKSzVyPUCuO|I3OTdizszN M3nWWnNCVkeHUh?=
CCRF-CEM M1zrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLFTWM2OD1yLke0OlYyKM7:TR?= MmDaV2FPT0WU
SW954 M4ryPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfCTWM2OD1yLke1PVk6KM7:TR?= MWjTRW5ITVJ?
IST-SL1 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrTd5BKSzVyPUCuO|c{PDhizszN M2LYOXNCVkeHUh?=
LAMA-84 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwN{e1Olch|ryP Ml31V2FPT0WU
Daudi M1PTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[5RYRKSzVyPUCuO|c3QDFizszN NGXRZW5USU6JRWK=
BC-3 NHzHfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwN{izNFgh|ryP MX\TRW5ITVJ?
HCC2998 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX0TXc1UUN3ME2wMlc5OzZizszN Mke1V2FPT0WU
NCI-H69 NYHWfGt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzlOHpDUUN3ME2wMlgxOTR5IN88US=> Moe1V2FPT0WU
CPC-N M1r4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPJTWM2OD1yLkiwOVI1KM7:TR?= NWXYV40xW0GQR1XS
NOMO-1 NGS4cpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W0SmlEPTB;MD64NVA5PCEQvF2= NXvhT4xvW0GQR1XS
CESS M2jGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOEGxPVch|ryP NGDicZRUSU6JRWK=
LC4-1 M3Hpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm0XpptUUN3ME2wMlg1ODB5IN88US=> NIToXpBUSU6JRWK=
BL-70 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OxSmlEPTB;MD64OVcxOiEQvF2= MYLTRW5ITVJ?
ES4 M3LtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3rRXNoUUN3ME2wMlg2QDZ6IN88US=> M1LLfHNCVkeHUh?=
HCE-T M2HEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfLTWM2OD1yLki3NVcyKM7:TR?= MUDTRW5ITVJ?
JAR MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jJSWlEPTB;MD64O|gzPyEQvF2= NU\xT4FsW0GQR1XS
ST486 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzme3VKSzVyPUCuPFc6OTdizszN MlP6V2FPT0WU
KS-1 NVXEbpFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7SUIJRUUN3ME2wMlg5ODl4IN88US=> MUDTRW5ITVJ?
GDM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwOEi2PFch|ryP MnTvV2FPT0WU
EHEB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLXTWM2OD1yLkmyOVg2KM7:TR?= M3jKVnNCVkeHUh?=
LB2518-MEL NFLuSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXrR|NKSzVyPUCuPVMzQDRizszN M4TBVHNCVkeHUh?=
GOTO NFLzVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrpWYFKSzVyPUCuPVUxPzZizszN NWOzbVhuW0GQR1XS
LXF-289 NWPLWFV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwOUW5NFEh|ryP NVfPdHV4W0GQR1XS
ES6 NWfxUpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrqcItKSzVyPUCuPVY1OzdizszN M2\4THNCVkeHUh?=
OS-RC-2 M4PXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD6TWM2OD1yLkm2PFMh|ryP M2Xh[HNCVkeHUh?=
DMS-153 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWxOYMzUUN3ME2wMlk4PDZ7IN88US=> M4PybHNCVkeHUh?=
SK-PN-DW M3vITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnWTWM2OD1yLkm3PFMyKM7:TR?= MWrTRW5ITVJ?
HH NV[wNYJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwOUi5OVkh|ryP MmO0V2FPT0WU
SH-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPqUHBXUUN3ME2xMlAzPDFizszN NUDsUJpVW0GQR1XS
MOLT-4 M1j5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr4bndKSzVyPUGuNFM1PTRizszN Moj2V2FPT0WU
TGW M1Hnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwMEe2O|Uh|ryP NUDwUHFwW0GQR1XS
L-540 NWDjTpVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfWfopJUUN3ME2xMlExPjB2IN88US=> MWjTRW5ITVJ?
PF-382 NVP6eYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMUG1NVMh|ryP M2Dkd3NCVkeHUh?=
LC-1F NHfxS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHYTWM2OD1zLkGyNFA4KM7:TR?= M2jZ[HNCVkeHUh?=
OVCAR-4 NXG4O4EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTFwMUOxOlUh|ryP NI\wcmhUSU6JRWK=
A4-Fuk NUjyNGlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwMUWzOlQh|ryP MoLrV2FPT0WU
HCC2218 M3mxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PDRmlEPTB;MT6xOlY1OSEQvF2= NFrWdXRUSU6JRWK=
HAL-01 M1TlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37h[mlEPTB;MT6xOlk1OyEQvF2= MlvIV2FPT0WU
IST-MEL1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXDTWM2OD1zLkG3OlU6KM7:TR?= M4mzU3NCVkeHUh?=
NCI-H719 NVXzRm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj1[WxOUUN3ME2xMlE4QDl6IN88US=> NUnaO|RqW0GQR1XS
EVSA-T M3TZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnJe2VDUUN3ME2xMlE5OTF2IN88US=> MW\TRW5ITVJ?
SK-NEP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rqSmlEPTB;MT6yNFI3PiEQvF2= MX\TRW5ITVJ?
OCUB-M NVPsUG5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H5RWlEPTB;MT6yNVQ5QSEQvF2= NYjrNoczW0GQR1XS
MEG-01 NGLjRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfBTWM2OD1zLkKyNVE5KM7:TR?= M2fkPXNCVkeHUh?=
no-10 M1vTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMkOxNVIh|ryP NXftXZVnW0GQR1XS
MHH-CALL-2 M4HmOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwMkS3NlEh|ryP M2fv[HNCVkeHUh?=
SK-N-DZ M4\aZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v3T2lEPTB;MT6yOFc4PiEQvF2= M1vGSXNCVkeHUh?=
SCLC-21H Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\tVm9KSzVyPUGuNlY1PzhizszN M1nXV3NCVkeHUh?=
CTV-1 NWS3W2pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u1[2lEPTB;MT6yO|QzPSEQvF2= MmK2V2FPT0WU
NB1 NV20SnpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnhO4pKSzVyPUGuNlc4OzJizszN NFHIeYRUSU6JRWK=
NCI-H64 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjJbZNKSzVyPUGuNlg1PjJizszN MlzsV2FPT0WU
MDA-MB-134-VI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqxTWM2OD1zLkK4OVc4KM7:TR?= MVLTRW5ITVJ?
LB2241-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwMki2OlMh|ryP MX3TRW5ITVJ?
8-MG-BA NIXEd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;QPXZKSzVyPUGuNlg5PjZizszN NFrW[ZRUSU6JRWK=
LP-1 NHz0V5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqyTWM2OD1zLkK5PVQ4KM7:TR?= NHHzNphUSU6JRWK=
LS-411N NIr2dmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnJSo1KSzVyPUGuN|A6QThizszN NEnne|hUSU6JRWK=
CAL-148 NIPNOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KwfmlEPTB;MT6zNlU1OiEQvF2= NFXIPXlUSU6JRWK=
NCI-H2171 NEDjNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DhU2lEPTB;MT6zOFUxOiEQvF2= M3mw[nNCVkeHUh?=
JiyoyeP-2003 M13KTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLZTWM2OD1zLkO1N|kh|ryP M2DHUXNCVkeHUh?=
NCI-H2107 NGPycIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjiN|dKSzVyPUGuN|U5QDNizszN Mn71V2FPT0WU
BB30-HNC NGXEc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5TWM2OD1zLkO4PVc5KM7:TR?= NIfGZ3dUSU6JRWK=
K-562 NFK4U45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\nWHZKSzVyPUGuN|kzOTlizszN MYnTRW5ITVJ?
PSN1 NVf2SW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{foWGlEPTB;MT60NlI5PyEQvF2= M1u2RnNCVkeHUh?=
HCC2157 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq1ZVdwUUN3ME2xMlQzPjlzIN88US=> MVrTRW5ITVJ?
SBC-1 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:5R3BKSzVyPUGuOFI4PDFizszN NV2xSG1HW0GQR1XS
MC116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvXOIFKSzVyPUGuOFM3OTVizszN Mk\mV2FPT0WU
KARPAS-422 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnDNFhKSzVyPUGuOFU{PThizszN NWrJTFQ{W0GQR1XS
LB996-RCC NIjYZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvpPWp{UUN3ME2xMlQ4OTB|IN88US=> NHLJZ|ZUSU6JRWK=
MSTO-211H Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLkWVk{UUN3ME2xMlQ4QTh5IN88US=> NVLpWpVCW0GQR1XS
BT-474 M2TXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwNUG3OlQh|ryP NHLCR2RUSU6JRWK=
A388 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvNTWM2OD1zLkWxPVQ2KM7:TR?= MYHTRW5ITVJ?
SJSA-1 M2LqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHzVnN3UUN3ME2xMlUzOjZizszN MlfEV2FPT0WU
COLO-829 M1rxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTFT2JKSzVyPUGuOVM2PjRizszN NHOxW2tUSU6JRWK=
KM-H2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXpTpNKSzVyPUGuOVY3PyEQvF2= M3;4V3NCVkeHUh?=
GR-ST NXnNTmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmiwTWM2OD1zLkW2PFIh|ryP NYewTZkyW0GQR1XS
RPMI-8866 NXm5PIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\oSXdxUUN3ME2xMlYxOTR2IN88US=> Mn3lV2FPT0WU
KG-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnoUpdKSzVyPUGuOlE6ODFizszN NWHaXo46W0GQR1XS
NCI-H82 NHLVW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwNkO0NFYh|ryP M3vNdHNCVkeHUh?=
LB1047-RCC NHrBS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwNkO0OVkh|ryP M4PTVHNCVkeHUh?=
KM12 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwNkS3JO69VQ>? NWPKdVB1W0GQR1XS
NB5 NV[3Z5RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f0XGlEPTB;MT62OVY4PyEQvF2= NXTTV4c3W0GQR1XS
HDLM-2 NFT1b5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDUXoFuUUN3ME2xMlY5OjhzIN88US=> Mkn3V2FPT0WU
KU812 NEjC[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwNkm2NFUh|ryP MUTTRW5ITVJ?
DB NH;uOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDzUHNiUUN3ME2xMlcxOzV|IN88US=> MVLTRW5ITVJ?
HD-MY-Z NWLoZVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7oXWpKUUN3ME2xMlc2OjN2IN88US=> MYfTRW5ITVJ?
KURAMOCHI MmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpZWZMUUN3ME2xMlc4OjB5IN88US=> NI[zZ|BUSU6JRWK=
ETK-1 NWHXXm5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nnWGlEPTB;MT63PFg4QSEQvF2= NFzRUmVUSU6JRWK=
SK-UT-1 NGfTfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLrXIdDUUN3ME2xMlc6Ozh6IN88US=> Mon0V2FPT0WU
HUTU-80 NIf1dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\RdmhKSzVyPUGuO|k2ODhizszN MWTTRW5ITVJ?
ES7 NFvobJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzkbphKSzVyPUGuPFA{ODJizszN M3zWZnNCVkeHUh?=
SW872 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K3XWlEPTB;MT64NVM6PSEQvF2= MVPTRW5ITVJ?
TK10 NYHUboJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSzTWM2OD1zLkizNVA5KM7:TR?= M4XNVXNCVkeHUh?=
LB831-BLC MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K3TGlEPTB;MT64N|U3OyEQvF2= M3fZSnNCVkeHUh?=
TE-9 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrVfGtKSzVyPUGuPFQ1OjJizszN MlLDV2FPT0WU
MLMA M2roSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILQc3JKSzVyPUGuPFgzOzRizszN MVXTRW5ITVJ?
D-542MG NWHRUIJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H6[mlEPTB;MT64PVM4OyEQvF2= Mkn1V2FPT0WU
EW-16 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfOdFhWUUN3ME2xMlkzPzJizszN M1fyfHNCVkeHUh?=
LOXIMVI NIDLW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;mTWM2OD1zLkmzNlgh|ryP MWXTRW5ITVJ?
GB-1 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPJRpJVUUN3ME2xMlk{QDZ4IN88US=> NInyRpVUSU6JRWK=
IST-SL2 M17UV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTzfYtKSzVyPUKuNFAzPjJizszN M2nme3NCVkeHUh?=
LAN-6 NFyxWZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJwMEG5OlYh|ryP NWDtSI06W0GQR1XS
NCI-H510A M33ZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL5TWM2OD1{LkC0OVAzKM7:TR?= NYX0XWtSW0GQR1XS
NCI-H1092 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPVdFFmUUN3ME2yMlA2OTJ2IN88US=> M{DHZnNCVkeHUh?=
HT M2fON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7DTWM2OD1{LkGwOFU1KM7:TR?= MV7TRW5ITVJ?
RL95-2 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TFdWlEPTB;Mj6xNVQ5OiEQvF2= Ml;OV2FPT0WU
NCI-H1355 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\L[VlKSzVyPUKuNVE4QTJizszN MXfTRW5ITVJ?
NCI-H720 M1;1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M131c2lEPTB;Mj6xOlg4OyEQvF2= NVXGNWdMW0GQR1XS
NCI-H1522 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fnOWlEPTB;Mj6yNVczOyEQvF2= NUPkdIpRW0GQR1XS
LB373-MEL-D NWnwfJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwMk[5NFIh|ryP M3j2R3NCVkeHUh?=
DG-75 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\zVGlEPTB;Mj6yO|E1QCEQvF2= MnTIV2FPT0WU
ML-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\mTWM2OD1{LkOyPFU2KM7:TR?= M{TL[3NCVkeHUh?=
SF126 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\UTWM2OD1{LkOzNFk1KM7:TR?= NHrCW2VUSU6JRWK=
MPP-89 M{XJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3Wd3dKSzVyPUKuN|MyPDVizszN MlrnV2FPT0WU
NCI-H345 NYXJV5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTNfGd1UUN3ME2yMlM{Ojd5IN88US=> NXnrZpM2W0GQR1XS
LS-123 NV3XS4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjneohsUUN3ME2yMlM1QTN4IN88US=> MXLTRW5ITVJ?
NB10 M2raOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHoTWM2OD1{LkSxNFkzKM7:TR?= NEnxeoFUSU6JRWK=
CGTH-W-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNOXY{UUN3ME2yMlQzOjZ5IN88US=> M1XYfHNCVkeHUh?=
CP66-MEL M33mWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwNEe3O{DPxE1? M4mwT3NCVkeHUh?=
L-428 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD6TWM2OD1{LkS4OVIyKM7:TR?= M4P5WXNCVkeHUh?=
DMS-79 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\jOmlEPTB;Mj61OFExOyEQvF2= NGCwelVUSU6JRWK=
NCI-H1882 NGf0V2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv5VnpKSzVyPUKuOlc2PjJizszN NGP6Z5BUSU6JRWK=
KGN M4DGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HxWWlEPTB;Mj63Olg4PiEQvF2= M4\pb3NCVkeHUh?=
EW-1 NWPpcY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH1dZlkUUN3ME2yMlc4ODh|IN88US=> NEPhSFVUSU6JRWK=
U-266 NFTkeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezSJZYUUN3ME2yMlg1QDJ|IN88US=> NFW2PXBUSU6JRWK=
COLO-320-HSR NX;hc4Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn24TWM2OD1{Lki1OlQyKM7:TR?= NGrl[ZJUSU6JRWK=
KMOE-2 NFXtd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;FW2lEPTB;Mj64O|cyOSEQvF2= MoPhV2FPT0WU
BB49-HNC NVLnUFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwOUK0PEDPxE1? NEDLPIRUSU6JRWK=
GI-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjMclVKSzVyPUKuPVI6PTdizszN MkPhV2FPT0WU
NCI-H1304 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Tle2lEPTB;Mz6wNFUyOSEQvF2= MXPTRW5ITVJ?
NCI-H2227 NFm5[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLRTWM2OD1|LkCyNFc6KM7:TR?= MoXaV2FPT0WU
U-87-MG MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7LTm9PUUN3ME2zMlA{PTF|IN88US=> NHnkW2JUSU6JRWK=
NCI-H747 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SxWWlEPTB;Mz6wOVIxPiEQvF2= NFTSUlZUSU6JRWK=
CTB-1 NUm1cYxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnydIFKSzVyPUOuNFU{PzZizszN MlX4V2FPT0WU
RPMI-8226 NELGVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwMUSzO|gh|ryP NVn6TlFyW0GQR1XS
NCI-H2141 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfOdnFRUUN3ME2zMlE3PTZ4IN88US=> NVTCXZRjW0GQR1XS
IST-MES1 NFTzVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNwMUiyO|kh|ryP M{HN[nNCVkeHUh?=
TE-5 NUjye3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPTdnNCUUN3ME2zMlIyOzR{IN88US=> M{PrZXNCVkeHUh?=
UACC-257 NVPQPYdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwNEO2OVkh|ryP NGKxdmxUSU6JRWK=
SK-N-FI Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrkRld7UUN3ME2zMlQ2OjJ5IN88US=> NFWxfnpUSU6JRWK=
MFH-ino NUfaZ3prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvF[pJKSzVyPUOuOFY2QDlizszN M2nGbXNCVkeHUh?=
SF268 NWTGWIt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwNEixO|Qh|ryP MYHTRW5ITVJ?
TE-12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\NTWM2OD1|LkWxOlk6KM7:TR?= Ml;2V2FPT0WU
NB6 NH[wOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwNUW1OlMh|ryP NVzHfJl2W0GQR1XS
DJM-1 NVLzZlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{flWmlEPTB;Mz61PVg6QSEQvF2= MnL1V2FPT0WU
MZ1-PC M2\HfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH0W5RKSzVyPUOuOlE3OjRizszN MljGV2FPT0WU
OCI-AML2 M1HKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1robWlEPTB;Mz62NlY4OSEQvF2= NEK0TI1USU6JRWK=
NCI-H1155 M{\TeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33hRmlEPTB;Mz63NFk1PyEQvF2= M4H0T3NCVkeHUh?=
RKO NFrPdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLPS3ZmUUN3ME2zMlc4OTh7IN88US=> MV3TRW5ITVJ?
ECC4 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7OOHhKSzVyPUOuPVcyQTVizszN NVzCdnNWW0GQR1XS
BB65-RCC NYDoVoZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjsVok3UUN3ME2zMlk4PTR5IN88US=> MmLuV2FPT0WU
EB-3 Mne5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3UTWM2OD1|Lkm5OlM{KM7:TR?= NGTuO5FUSU6JRWK=
SHP-77 M2rPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PlT2lEPTB;ND6wNFUzPCEQvF2= MkTNV2FPT0WU
NCI-H2196 M{nze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDGUo9KSzVyPUSuNFU3OjVizszN NHfIeoNUSU6JRWK=
GI-ME-N NXj6eIZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorZTWM2OD12LkC2N|k6KM7:TR?= MorRV2FPT0WU
MN-60 NGfYfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRwMUC4O{DPxE1? M3jPXXNCVkeHUh?=
NCI-H1694 NYHSboFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK4ZXFKSzVyPUSuNVM1ODVizszN NWDNUXpDW0GQR1XS
LU-65 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHTTWM2OD12LkG1N|MzKM7:TR?= NYPj[HFUW0GQR1XS
NCI-H1436 NV;FWHJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GyU2lEPTB;ND6xPFM{OyEQvF2= NXzHc3A4W0GQR1XS
KINGS-1 NYXSbXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfId|RCUUN3ME20MlMyPDN{IN88US=> NUP4O5RPW0GQR1XS
GT3TKB NUHMV2RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPxcVdKSzVyPUSuN|MzPjhizszN MkW0V2FPT0WU
Becker M3HM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X2[2lEPTB;ND6zO|MyOiEQvF2= NHrSbnpUSU6JRWK=
HCC1187 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXiNYRKSzVyPUSuPFk3PTdizszN NGDMW4RUSU6JRWK=
D-502MG NGTTTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDHVJVmUUN3ME21MlAxPDF4IN88US=> M4\acnNCVkeHUh?=
VA-ES-BJ NXKwTWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTVwMUO3O|gh|ryP M3;yTnNCVkeHUh?=
NB7 NGD0NXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D4cGlEPTB;NT6xOFEyOiEQvF2= NWW0OFZGW0GQR1XS
SW962 M1PJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrBeJJoUUN3ME21MlM5QDF2IN88US=> M2rUN3NCVkeHUh?=
no-11 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW2TWM2OD13Lke2N|Q{KM7:TR?= MorTV2FPT0WU
KNS-81-FD M{fQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;KWmlEPTB;NT65NFY6PCEQvF2= MXvTRW5ITVJ?
COLO-684 NEHONmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL4TWM2OD13Lkm5OFk1KM7:TR?= NY\hc2Z3W0GQR1XS
D-263MG NXrPUYV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjnbIc4UUN3ME22MlA5QDl3IN88US=> MYLTRW5ITVJ?
EW-24 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L3WGlEPTB;Nj6yPFUyKM7:TR?= MXTTRW5ITVJ?
TE-10 NFqzW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjze3hsUUN3ME22MlQzPjJ|IN88US=> NWPVd4o6W0GQR1XS
EKVX M4fIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTZwNE[zNlEh|ryP NVfRcFY2W0GQR1XS
NCI-H1648 NUHzVHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXzTWM2OD14Lk[3OVU4KM7:TR?= M3HINHNCVkeHUh?=
LB771-HNC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnEemZYUUN3ME22MlkzOzBzIN88US=> NFHjfI5USU6JRWK=
SK-MEL-1 M3Tvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\B[45DUUN3ME24MlE{OTZ4IN88US=> NX\pN5JKW0GQR1XS
COLO-668 NWXkRo93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljNTWM2OD16LkK3O|g3KM7:TR?= M1;QOnNCVkeHUh?=
EW-12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7yNYYzUUN3ME24MlQxQDB|IN88US=> M17mNXNCVkeHUh?=
A253 M17ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRThwOES2OlEh|ryP NHn2OZNUSU6JRWK=
NCI-H2126 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HNXWlEPTB;OD64PVMyQSEQvF2= NInvNoZUSU6JRWK=
Calu-6 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRThwOUmwOFIh|ryP MkXzV2FPT0WU
NCI-H23 NHrqblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fUXWlEPTB;OT6xO|c1PiEQvF2= M4T2e3NCVkeHUh?=
WSU-NHL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTlwN{e0O|gh|ryP NHG5[5hUSU6JRWK=
MMAC-SF MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTqdFZKSzVyPUmuPVc6ODRizszN NHfVUIZUSU6JRWK=
SK-LMS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLjTWM2OD1zMD6yPFM1KM7:TR?= MmOyV2FPT0WU
GCIY M2PyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPXeHBKSzVyPUGwMlU6OjRizszN NXzWOYZ2W0GQR1XS
TE-15 NIPqR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTK[HZKSzVyPUGxMlYxODRizszN MV7TRW5ITVJ?
EoL-1-cell M2jBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLvTWM2OD1zMT63OlgzKM7:TR?= M2P6enNCVkeHUh?=
NCI-H2081 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HlNGlEPTB;MUGuO|c5PiEQvF2= MmXxV2FPT0WU
EW-3 NWTFO5lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTL[XFtUUN3ME2xNk4zPDZ|IN88US=> NUnjdYFPW0GQR1XS
CAS-1 NX70RnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXvUpRKSzVyPUGyMlM3OzFizszN MUHTRW5ITVJ?
C2BBe1 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj2TWM2OD1zMj62NVMyKM7:TR?= NVKxPHVrW0GQR1XS
D-247MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfGfWRKSzVyPUGyMlc6PTJizszN MV;TRW5ITVJ?
NCI-SNU-5 M2DISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nSGlEPTB;MUKuPFAyOyEQvF2= NEflb5pUSU6JRWK=
LS-1034 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF2LkO5O|Uh|ryP NFjIVW1USU6JRWK=
EW-18 M2TzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjSW5BKSzVyPUG0MlQ1QCEQvF2= NGq2dFBUSU6JRWK=
Raji Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF2LkWwOFkh|ryP NUnr[YtFW0GQR1XS
D-283MED M33xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF2Lk[yO|Eh|ryP NXHNV5hGW0GQR1XS
MZ2-MEL NWWwdJFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF2Lkm2PVYh|ryP MWrTRW5ITVJ?
NCI-SNU-16 NEPk[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF3LkS2N|Mh|ryP M4C4fXNCVkeHUh?=
P30-OHK NWLnd4g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLmTWM2OD1zNz63PFMyKM7:TR?= MmrwV2FPT0WU
RXF393 NYXyPFljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zLSGlEPTB;MUmuNFE5PiEQvF2= MVvTRW5ITVJ?
NCI-H1395 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfQfVRKSzVyPUKwMlY4ODNizszN MV;TRW5ITVJ?
U-698-M MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf0bYVKSzVyPUKwMlcxPzVizszN MYLTRW5ITVJ?
NCI-SNU-1 NWrUZnFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJyLkeyNlMh|ryP M{PVU3NCVkeHUh?=
SW684 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITQV3ZKSzVyPUKxMlE4OTZizszN NVXkPWRnW0GQR1XS
NCI-H716 NWjkbGNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rGe2lEPTB;MkGuN|E2PCEQvF2= NYjNTW9jW0GQR1XS
JVM-2 MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELHfWZKSzVyPUKxMlQyOzNizszN MojDV2FPT0WU
NCI-H1581 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT3TWM2OD1{Mj60NVQ5KM7:TR?= MWPTRW5ITVJ?
CA46 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXMOVFxUUN3ME2zNU43QTN4IN88US=> NVrHdnFYW0GQR1XS
SNB75 NGX6dY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ndYxqUUN3ME2zN{43PTB|IN88US=> NIjifGpUSU6JRWK=
KNS-42 NG\IT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN3Lkm2NlQh|ryP NEXYV3BUSU6JRWK=
TUR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTN4LkC1NlEh|ryP M1LzVXNCVkeHUh?=
REH M2\LTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu5S5JpUUN3ME2zO{45OjFzIN88US=> MkH6V2FPT0WU
EW-22 NIX1S5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfWTWM2OD12Mj6yPFg2KM7:TR?= NHXiW|VUSU6JRWK=
NCI-H446 NF\ySYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTR{Lke4OVMh|ryP NI[xS3JUSU6JRWK=
ES3 NYXBVZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR|LkGzN|kh|ryP M3Lze3NCVkeHUh?=
EW-11 NWPKTIFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC3NWFKSzVyPUS0MlgzOThizszN NX3JRmtwW0GQR1XS
RH-1 NFPldYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDlXHhKSzVyPUS3MlU5OTJizszN NIjYOItUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID